JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Salvati, P.
Right arrow Articles by Fariello, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salvati, P.
Right arrow Articles by Fariello, R. G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-ALANINE
*GLUTAMIC ACID HYDROCHLORIDE
*POTASSIUM CHLORIDE

Vol. 288, Issue 3, 1151-1159, March 1999

Biochemical and Electrophysiological Studies on the Mechanism of Action of PNU-151774E, A Novel Antiepileptic Compound

P. Salvati, R. Maj, C. Caccia, M. A. Cervini, M. G. Fornaretto, E. Lamberti, P. Pevarello, G. A. Skeen, H. S. White, H. H. Wolf, L. Faravelli, M. Mazzanti, E. Mancinelli, M. Varasi and R. G. Fariello

Central Nervous System Preclinical Research (P.S., R.M., C.C., M.A.C., M.G.F., E.L.), Department of Chemistry (P.P., M.V.), Pharmacia & Upjohn S.p.A. Nerviano (MI), Italy; Department of Pharmacology and Toxicology (G.A.S., H.S.W., H.H.W.), National Institutes of Health-National Institute of Neurological Disorders and Stroke Anticonvulsant Screening Project, University of Utah, Salt Lake City, Utah; Department of General Physiology and Biochemistry (L.F., M.M., E.M.), University of Milano, Milan, Italy; Department of Neuroscience, Istituti Clinici di Perfezionamento (R.G. F.), Milan, Italy; and Department of Neurology, T. Jefferson University (R.G.F.), Philadelphia, Pennsylvania

PNU-151774E [(S)-(+)-2-(4-(3-fluorobenzyloxy)benzylamino)propanamide methanesulfonate], a new anticonvulsant that displays a wide therapeutic window, has a potency comparable or superior to that of most classic anticonvulsants. PNU-151774E is chemically unrelated to current antiepileptics. In animal seizure models it possesses a broad spectrum of action. In the present study, the action mechanism of PNU-151774E has been investigated using electrophysiological and biochemical assays. Binding studies performed with rat brain membranes show that PNU-151774E has high affinity for binding site 2 of the sodium channel receptor, which is greater than that of phenytoin or lamotrigine (IC50, 8 µM versus 47 and 185 µM, respectively). PNU-151774E reduces sustained repetitive firing in a use-dependent manner without modifying the first action potential in hippocampal cultured neurons. In the same preparation PNU-151774E inhibits tetrodotoxin-sensitive fast sodium currents and high voltage-activated calcium currents under voltage-clamp conditions. These electrophysiological activities of PNU-151774E correlate with its ability to inhibit veratrine and KCl-induced glutamate release in rat hippocampal slices (IC50, 56.4 and 185.5 µM, respectively) and calcium inward currents in mouse cortical neurons. On the other hand, PNU-151774E does not affect whole-cell gamma -aminobutryic acid- and glutamate-induced currents in cultured mouse cortical neurons. These results suggest that PNU-151774E exerts its anticonvulsant activity, at least in part, through inhibition of sodium and calcium channels, stabilizing neuronal membrane excitability and inhibiting transmitter release. The possible relevance of these pharmacological properties to its antiepileptic potential is discussed.


0022-3565/99/2883-1151$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
D. R. Riddall, M. J. Leach, and J. Garthwaite
A Novel Drug Binding Site on Voltage-Gated Sodium Channels in Rat Brain
Mol. Pharmacol., January 1, 2006; 69(1): 278 - 287.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. A. Smith and R. S. Obach
SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING
Drug Metab. Dispos., October 1, 2005; 33(10): 1409 - 1417.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
F. Stocchi, G. Arnold, M. Onofrj, H. Kwiecinski, A. Szczudlik, A. Thomas, U. Bonuccelli, A. Van Dijk, C. Cattaneo, P. Sala, et al.
Improvement of motor function in early Parkinson disease by safinamide
Neurology, August 24, 2004; 63(4): 746 - 748.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.